(The Center Square) – A limited ban on stock trading by Congress might get a vote next year after a 2012 law did not do enough to stem the practice that critics say is legal insider trading.
The Center Square has been investigating the trades of lawmakers on key committees, finding trades that raise questions about the actions and timing.
Since 2022, members of Congress have introduced measures to ban lawmakers from trading stocks altogether. Both last year and this July, the Senate Homeland and Governmental Affairs Committee advanced a stock-ban bill.
Neither chamber has scheduled a vote on legislation despite overwhelming public support for a stock ban. According to Politico, House Majority Leader Steve Scalise, a Louisiana Republican, said he expects by early next year to vote on a bill that would permit lawmakers to keep stocks they own but bar them from buying new stocks. They would be required to provide seven days of notice before selling their current stocks.
U.S. Rep. Anna Paulina Luna, a Florida Republican, filed what is known as a discharge petition to force House leadership to vote on a bill that would prohibit members of Congress, spouses and dependent children from trading stocks. As of Dec. 22, the petition has 74 signatories, far short of the 218 required.
A statute passed more than a decade ago that was supposed to address the issue of Congressional stock trading has come under fire for being too lax as lawmakers continue to trade before key announcements, investigations by The Center Square found.
Tylenol trades
In the last half year alone, three lawmakers each dumped stock in Kenvue Inc., the Summit, New Jersey-based maker of acetaminophen, the primary active ingredient in Tylenol, ahead of a government announcement questioning whether the use of the drug by pregnant women is linked to autism.
They did so despite recommendations from most financial analysts that investors buy or hold their shares. Since the government’s announcement, Kenvue’s stock has tumbled from roughly $21 a share this summer to less than $17 a share as of Dec. 22, a 19% decrease.
U.S. Sen. Sheldon Whitehouse of Rhode Island and U.S. Rep. Ro Khanna of California, both Democrats, reported that their wives sold $1,001 to $15,000 of the company’s stock in late August.
That was less than a month before Secretary of Health and Human Services Robert F. Kennedy, Jr., said the federal government would slap a label on Tylenol tablets warning pregnant mothers that taking the popular painkiller could cause their unborn children to develop autism. The overwhelming consensus among scientists and medical researchers is there is no causal link between using Tylenol and developing autism.
A Whitehouse spokeswoman, Meaghan McCabe, did not return two emails seeking comment, while a spokeswoman, Sarah Drory, for Khanna issued a statement.
“Rep. Khanna doesn’t trade stocks, has pushed for years for a ban on trading and for the TRUST in Congress Act requiring independently managed trusts, and his voting record shows he is bold and principled in standing up for his values,” Drory said.
U.S. Rep. Scott Franklin, a Florida Republican, reported that through a joint account with his wife, he sold $1,001 to $15,000 of stock in Kenvue on June 16. He dumped the stock while serving as the vice chairman of a House Appropriations subcommittee that oversees the Food and Drug Administration’s budget, the federal agency that regulates Tylenol.
A Franklin spokeswoman, Melissa Tarte, did not return an email for comment.
